Names and pronunciation
B rems (byoo-pre-nor′feen) Belbuca, Buprenex, Butrans, Probuphine, Sublocade
Source page 201
Loading InternPractice…
Individual generic drug information
Extracted information for buprenorphine only.
B rems (byoo-pre-nor′feen) Belbuca, Buprenex, Butrans, Probuphine, Sublocade
Source page 201
Func. class.: Opioid analgesic, partial agonist
Source page 201
Chem. class.: Thebaine derivative Controlled Substance Schedule III
Source page 201
ACTION: Depresses pain impulse transmission at the spinal cord level by interacting with opioid receptors, partial agonist at μ-opioid receptor
Source page 201
USES: Moderate to severe pain, opiate agonist withdrawal/dependence
Source page 201
Unlabeled uses: Cocaine withdrawal
Source page 201
Extracted information for buprenorphine only.
CONTRAINDICATIONS: Hyper- sensitivity, ileus, status asthmaticus
Source page 201
Black Box Warning: Respiratory depres- sion Precautions: Pregnancy, breastfeeding, substance abuse/alcoholism, increased intracranial pressure, MI (acute), severe heart disease, respiratory depression, renal/hepatic/pulmonary disease, hypo- thyroidism, Addison’s disease, QT pro- longation, accidental exposure, neonatal opioid withdrawal syndrome Black Box Warning: Potential for over- dose/poisoning, substance abuse, IM, coadministration with other CNS depres- sants, implant insertion and removal Black Box Warning: Accidental expo- sure: keep away from children and pets; may be fatal • I&O ratio; check for decreasing out- put; may indicate urinary retention • Bowel pattern; severe constipation can occur • CNS changes, dizziness, drowsiness, hal- lucinations, euphoria, LOC, pupil reaction; withdrawal in opioid-dependent persons • Allergic reactions: rash, urticaria Black Box Warning: Respiratory dys- function: respiratory depression, char- acter, rate, rhythm; notify prescriber if respirations are <12/min, may be fatal Black Box Warning: Potential for over- dose may occur from chewing, swallow- ing, snorting, or injecting extracted product from TD formulation • QT prolongation: in those taking class Ia, III antidysrhythmics; patients with hy- pokalemia, cardiac instability (TD), max TD 20 mcg/hr q7day • Beers: avoid in older adults unless safer alternatives are not available, may cause impaired psychomotor function, syncope • Pregnancy/breastfeeding: avoid use in pregnancy and breastfeeding; in those using product and breastfeeding, watch infant for decreased respiration, lethargy, decreased heart rate Black Box Warning: That psychologic de- pendence leading to substance abuse may result when used for extended periods; that long-term use is not recommended • That product can cause serious breathing problems; call provider right away if feeling faint, dizzy, or if breath- ing gets much slower than normal • To avoid hazardous activities such as driving unless reaction is known • Do not start new meds/herbs without prescriber approval; do not double, skip doses • Start stool softener/laxatives to lessen constipation • SL route: to place under tongue and allow to dissolve • Transdermal route: how to apply and dispose of patch; not to use a heating pad or other heat source; do not cut
Source pages 201, 204
SIDE EFFECTS CNS: Drowsiness, dizziness, confu- sion, headache, sedation, euphoria, hallucinations, strange dreams CV: Palpitations, QT prolongation, hypo/ hypertension EENT: Tinnitus, blurred vision, miosis, diplopia GI: Nausea, vomiting, anorexia, consti- pation, dry mouth, hepatotoxicity GU: Urinary retention INTEG: Rash, diaphoresis, pruritus RESP: Respiratory depression, bronchospasm MISC: Anaphylaxis, angioedema, dependency
Source page 203
INTERACTIONS Increase: effect with other CNS depres- sants—alcohol, opioids, sedative/hyp- notics, antipsychotics, skeletal muscle relaxants, MAOIs Increase: buprenorphine effect— CYP3A4 inhibitors (erythromycin, indinavir, ketoconazole, ritonavir, saquinavir) Increase: QT prolongation—class IA, III antidysrhythmics Increase: serotonin syndrome 5-HT3 antagonists, linezolid, methylene blue, MAOIs, SSRIs, SNRIs, tricyclics Decrease: buprenorphine effect— CYP3A4 inducers (carBAMazepine, PHE- Nobarbital, phenytoin, rifampin) Drug/Herb Increase: CNS depression—chamomile, kava, St. John’s wort
Source pages 203, 204
TREATMENT OF OVERDOSE: Naloxone 0.4 mg ampule diluted in 10 mL 0.9% NaCl given by direct IV push 0.02 mg q2min (adult)
Source page 204
Extracted information for buprenorphine only.
DOSAGE AND ROUTES Moderate/severe pain • Adult/child ≥13 yr: IM/IV 0.3 mg q4- 6hr as needed: TD each patch is worn for 7 days (moderate-severe pain); opioid- naive patients (those taking <30 mg of oral morphine or equivalent before begin- ning treatment with TD buprenorphine), 5 mcg/hr q7days, overestimating dose can be fatal; conversion from other opiate agonist therapy, titrate from other opi- oids for up to 7 days to no more than 30 mg oral morphine or equivalent before beginning TD therapy, begin with 5 mcg/hr q7days; for those with daily dose of 30-80 mg oral morphine or equivalent, start with 10 mcg/hr q7days; for those taking >80 mg oral morphine or equivalent, start with 20 mcg/hr q7days • Geriatric/debilitated patients: IM/IV 0.15 mg slowly • Child 2-12 yr: IM/IV 2-6 mcg/kg q4-8hr, give IV over ≥2 min Opioid dependence Adult: SL 8 mg on day 1 and 16 mg on day 2, titrate in increments of 2 or 4 mg up or down to needed, maintenance dose 4-24 mg SL daily Hepatic dose Adult TD (mild-moderate): 5 mcg/hr system initially disease): Buccal (severe hepatic decrease dose by 50%, titrate upward by 75 mcg q12hr ≥q4days
Source pages 201, 202
Available forms: Injection 0.3 mg/mL (1-mL vials); SL tablet 2, 8 mg as base; TD system 5, 7.5, 10, 15, 20 mcg/hr (weekly); dissolving film (buccal) 75, 150, 300, 450, 600, 750, 900 mcg; solution for injection, extended release 100 mg/0.5 mL, 300 mg/1.5 mL; SD implant 74.2 mg/implant
Source page 202
Administer: SL route • Do not chew; dissolve under tongue, use 2 or more at same time Transdermal route (REMS) • Apply to clean, dry, intact skin; each patch should be worn for 7 days, do not exceed dose, QTC prolongation may oc- cur; do not apply direct heat source to patch, will increase absorption of prod- uct, may use first-aid tape if edge of patch is not adhering • Apply to upper outer arm, upper chest/back, or side of chest Subcut route (extended-release injection—Sublocade) • Inject only in abdominal region. DO NOT use IM/IV • Visually inspect for particulate matter, discoloration before use; product is clear, colorless to yellow to amber solution • Give monthly with a minimum of 26 days between doses • Use only the syringe and safety needle included. Do not attach the needle until time of use • Do not inject into an area where skin is irritated, reddened, bruised, infected, or scarred • Do not rub area after injection • To avoid irritation, rotate injection site with each injection • Injection site should be examined for infection, evidence of tampering, or at- tempts to remove the depot • Storage: Store unopened prefilled syringes in the refrigerator in original packaging; do not freeze. Discard injec- tion if left at room temperature for lon- ger than 7 days Subdermal route (Probuphine) • Inserted in inner side of upper arm • Maintenance dose must be 8 mg/day or less • Use guideline from manufacturer • Available from REMS program (844- 859-6341), health care professional must complete training program • Inserts are removed after 6 mo, if other insert is not used, use transmucosal IM route • In deep muscle mass IV, direct route • Give undiluted over ≥2 min, titrate to patient response; rapid injection will in- crease side effects • With antiemetic if nausea, vomiting occur • When pain is beginning to return; de- termine dosage interval by patient re- sponse Y-site compatibilities: Acyclovir, alfent- anil, allopurinol, amifostine, amikacin, aminocaproic acid, amphotericin B lipo- some (AmBisome), anidulafungin, ascor- bic acid injection, atenolol, atracurium, atropine, aztreonam, benztropine, bivali- rudin, bleomycin, bumetanide, butorpha- nol, calcium chloride/gluconate, CARBOplatin, cefamandole, ceFAZolin, cefepime, cefotaxime, cefoTEtan, cefOXitin, cefTAZi- dime, ceftizoxime, cefTRIAXone, cefurox- ime, chloramphenicol, chlorproMAZINE, cimetidine, cisatracurium, CISplatin, cladribine, clindamycin, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytara- bine, D5W-dextrose 5%, DACTINomycin, DAPTOmycin, dexamethasone, dexme- detomidine, digoxin, diltiazem, diphen- hydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doxacurium, DOXOrubicin HCl, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, ertapenem, erythromycin, esmolol, etoposide, famotidine, fenoldo- pam, fentaNYL, filgrastim, fluconazole, fludarabine, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, heparin, hydrocortisone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cila statin, inamrinone, insulin (regular), iri- notecan, isoproterenol, ketorolac, labet- alol, lactated Ringer’s injection, levofloxacin, lidocaine, linezolid, LORaz- epam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperi- dine, metaraminol, methicillin, metho- trexate, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, mezlocil- lin, miconazole, midazolam, milrinone, minocycline, mitoXANtrone, morphine, moxalactam, multiple vitamins injection, mycophenolate mofetil, nafcillin, nalbu- phine, naloxone, nesiritide, netilmicin, nitroglycerin, nitroprusside, norepineph- rine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, palonosetron, pami- dronate, pancuronium, papaverine, PEMEtrexed, penicillin G potassium/ sodium, pentamidine, pentazocine, phen- ylephrine, phytonadione, piperacillin, piperacillin-tazobactam, polymyxin B, potassium chloride, procainamide, pro- chlorperazine, promethazine, propofol, propranolol, protamine, pyridoxine, quiN- IDine, ranitidine, remifentanil, Ringer’s injection, riTUXimab, rocuronium, sodium acetate, succinylcholine, SUFent- anil, tacrolimus, teniposide, theophylline, thiamine, thiotepa, ticarcillin, ticarcillin- clavulanate, tigecycline, tirofiban, TNA (3-in-1), tobramycin, tolazoline, TPN, B trastuzumab, trimetaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, voriconazole
Source pages 202, 203
Extracted information for buprenorphine only.
Assess: • Pain: intensity, location, type before treatment, after 5, 15, 30 min (IV); need for pain medication, tolerance
Source page 204
Evaluate: • Therapeutic response: decrease in pain, decreased withdrawal symptoms
Source page 204
CLINICAL CONSIDERATIONS
Source page 204
Patient and caregiver information: • To report any symptoms of CNS changes, allergic reactions
Source page 204
Extracted information for buprenorphine only.
PHARMACOKINETICS Metabolized in liver by CYP3A4, excreted by kidneys and in feces, crosses placenta, excreted in breast milk, half-life 2½-3½ hr, 96% bound to plasma proteins IM: Onset 15 min, peak 1 hr, duration 6-10 hr SL: Onset, peak, duration unknown, half-life 37 hr IV: Onset 1 min, peak 5 min, duration 6 hr, half-life 2.2 hr TD: Half-life 26 hr Epidural: Duration dose dependent
Source page 203
Filter the extracted dose blocks for this individual drug.
Moderate/severe pain
• Geriatric/debilitated patients: IM/IV 0.15 mg slowly
Candidate age grouping · source pages 201, 202